Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
Abstract The use of the adjuvant therapeutic antibody trastuzumab in breast cancer is associated with a range of cardiotoxic side effects despite successfully reducing the severity of outcomes cancer patients,. The most common cardiac effect, a reduction in left ventricular ejection fraction (LVEF),...
Main Authors: | Holden Eaton, Kerstin Nina Timm |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-04-01
|
Series: | Cardio-Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40959-023-00172-3 |
Similar Items
-
Potential Ameliorating Role of Spironolactone in Trastuzumab-induced Cardiotoxicity: A Narrative Review
by: Amir Ghabousian, et al.
Published: (2021-11-01) -
Cancer Therapy-Induced Cardiotoxicity—A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy
by: Anurag Choksey, et al.
Published: (2021-12-01) -
Chemotherapy-induced cardiotoxic effect in breast cancer patients treated with trastuzumab (Herceptin) by MRI
by: Mohamed Aboulfotouh Mourad, et al.
Published: (2023-12-01) -
Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
by: Wei‐Ting Chang, et al.
Published: (2021-12-01) -
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
by: Santino Minichillo, et al.
Published: (2017-11-01)